

Zelira Therapeutics Ltd

18:05 06 Aug 2020

Three medical cannabis companies in focus at Proactive's webinar on August 11

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) is one of three companies set to present at Proactive's medical cannabis focussed webinar on Tuesday, August 11, along with MGC Pharmaceuticals Ltd (ASX:MXC) and Southern Cannabis Holdings.

The Proactive CEO Investor Sessions is an online variant of the popular conference format the media company has run for over a decade and enables communication between interested investors and some of Australia's most innovative businesses.

The three companies will outline their plans and focus on the global medical cannabis market, which is expected to grow at a compound annual growth rate (CAGR) of 15.4% from 2019 to 2025, according to Market Research Future (MRFR).

The medical cannabis market is expected to be worth US\$52.35 billion by 2025, as per the MRFR report.

Zelira Therapeutics

Zelira Therapeutics is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets.

Managing director and CEO Richard Hopkins will talk about the company's plan to launch its Zenivol™ and HOPE™ range of products into the Australian market by the end of the current quarter.

The developer of clinically validated cannabinoid-derived medicines has entered into the necessary manufacturing and distribution agreements and has also finalised branding and packaging details.

MGC Pharmaceuticals

MGC Pharmaceuticals is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines.

Co-founder and managing director Roby Zomer will outline the company's progress on its phase II clinical trial in COVID-19 patients at the webinar.

The phase II clinical trial that began in Israel in May 2020 is progressing on schedule.

MGC's phase II clinical trial at the Mahatma Gandhi Mission's Medical College & Hospital in India is also moving forward.

Southern Cannabis Holdings

Tim Drury, director and CEO of Southern Cannabis Holdings (SCH), a vertically integrated group of medical cannabis

Price: 0.075

Market Cap: \$88.9 m

1 Year Share Price Graph



Share Information

Code: ZLD

Listing: ASX

52 week High Low
0.1 0.022

Sector: Cannabis

Website: www.zeldatherapeutics.com

Company Synopsis:

Zelira Therapeutics Ltd (ASX:ZLD) is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets.

action@proactiveinvestors.com.au

companies based in Sydney, will present at the webinar.

The company builds, integrates and operates high value brands across the cannabis value chain.

SCH companies include Cannabis Access Clinics, Australia's first and largest network of medicinal cannabis clinics, Applied Cannabis Research, a specialist contract research organisation dedicated to assisting medicinal cannabis companies, and FreshLeaf Analytics, Australia's leading source of data and information about the medicinal cannabis industry.

Webinar registration

To register for the August 11 webinar, please [click here](#).

The webinar will also be live-streamed on the Proactive YouTube channel, which can then be viewed anytime following the presentation.

For additional information, please contact John Phillips at Proactive on john.phillips@proactiveinvestors.com or call 0431 597 771.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).